S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)

Alpine Immune Sciences - ALPN Stock Forecast, Price & News

$7.11
-0.10 (-1.39%)
(As of 10/5/2022 03:16 PM ET)
Add
Compare
Today's Range
$7.04
$7.19
50-Day Range
$6.89
$8.90
52-Week Range
$6.00
$14.40
Volume
3,135 shs
Average Volume
143,858 shs
Market Capitalization
$216.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00

Alpine Immune Sciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
195.8% Upside
$21.00 Price Target
Short Interest
Bearish
7.00% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.12) to ($1.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

641st out of 1,087 stocks

Pharmaceutical Preparations Industry

305th out of 546 stocks

ALPN stock logo

About Alpine Immune Sciences (NASDAQ:ALPN) Stock

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.

Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Stock News Headlines

Alpine Immune Sciences raising $100M in public offering
Did Biden Bet the Future of America on the "Lithium Triangle"?
FREE investor's report details the plan to cut more ties with China and how it could create the next boom for early investors. But you must act fast.
Nevada Desert more Valuable than Wall Street or Silicon Valley?
It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar.
Alpine Immune Sciences Inc - Stock Quote ALPN
See More Headlines
Receive ALPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alpine Immune Sciences and its competitors with MarketBeat's FREE daily newsletter.

ALPN Company Calendar

Last Earnings
8/11/2022
Today
10/05/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALPN
Employees
85
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$21.00
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$17.00
Forecasted Upside/Downside
+195.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-50,330,000.00
Net Margins
-169.82%
Pretax Margin
-164.93%

Debt

Sales & Book Value

Annual Sales
$23.44 million
Book Value
$4.14 per share

Miscellaneous

Free Float
13,772,000
Market Cap
$216.14 million
Optionable
Not Optionable
Beta
1.51

Key Executives

  • Dr. Mitchell H. Gold M.D. (Age 54)
    Exec. Chairman & CEO
    Comp: $823.7k
  • Dr. Stanford Peng M.D. (Age 51)
    Ph.D., Pres and Head of R&D
    Comp: $1.11M
  • Mr. Paul Rickey (Age 43)
    Sr. VP, CFO, Treasurer & Sec.
    Comp: $586k
  • Dr. Wayne R. Gombotz (Age 63)
    Chief Technology Officer
  • Mr. Alexander Sharif
    Director of Investor Relations & Corp. Devel.
  • Dr. Remy Durand Ph.D.
    Chief Bus. Officer
  • Dr. Pamela Holland Ph.D.
    Sr. VP of Research
  • Dr. Andrew Seth Sandler M.D. (Age 57)
    Chief Medical Officer













ALPN Stock - Frequently Asked Questions

Should I buy or sell Alpine Immune Sciences stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alpine Immune Sciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALPN shares.
View ALPN analyst ratings
or view top-rated stocks.

What is Alpine Immune Sciences' stock price forecast for 2022?

2 Wall Street analysts have issued twelve-month price objectives for Alpine Immune Sciences' shares. Their ALPN share price forecasts range from $17.00 to $25.00. On average, they predict the company's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 195.8% from the stock's current price.
View analysts price targets for ALPN
or view top-rated stocks among Wall Street analysts.

How have ALPN shares performed in 2022?

Alpine Immune Sciences' stock was trading at $13.85 at the beginning of 2022. Since then, ALPN stock has decreased by 48.7% and is now trading at $7.10.
View the best growth stocks for 2022 here
.

When is Alpine Immune Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our ALPN earnings forecast
.

How were Alpine Immune Sciences' earnings last quarter?

Alpine Immune Sciences, Inc. (NASDAQ:ALPN) issued its quarterly earnings data on Thursday, August, 11th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by $0.21. The biotechnology company had revenue of $5.29 million for the quarter, compared to analysts' expectations of $8.64 million. Alpine Immune Sciences had a negative net margin of 169.82% and a negative trailing twelve-month return on equity of 47.34%.

What other stocks do shareholders of Alpine Immune Sciences own?
What is Alpine Immune Sciences' stock symbol?

Alpine Immune Sciences trades on the NASDAQ under the ticker symbol "ALPN."

How do I buy shares of Alpine Immune Sciences?

Shares of ALPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alpine Immune Sciences' stock price today?

One share of ALPN stock can currently be purchased for approximately $7.10.

How much money does Alpine Immune Sciences make?

Alpine Immune Sciences (NASDAQ:ALPN) has a market capitalization of $215.84 million and generates $23.44 million in revenue each year. The biotechnology company earns $-50,330,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis.

How can I contact Alpine Immune Sciences?

Alpine Immune Sciences' mailing address is 188 East Blaine Street Suite 200, Seattle WA, 98102. The official website for the company is www.alpineimmunesciences.com. The biotechnology company can be reached via phone at (206) 788-4545, via email at laurence@gilmartinir.com, or via fax at 303-440-8399.

This page (NASDAQ:ALPN) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.